SCHEMBL13367481

SCHEMBL13367481

Cc1cccc(N(C)c2ncncn2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 6/20 0.50
CSF1R P07333 5/20 0.50
TSHR P16473 2/20 0.47
CLK1 P49759 1/20 0.44
CLK2 P49760 1/20 0.44
DYRK1A Q13627 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
DYRK1B Q9Y463 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.42
TNNI3K Q59H18 2/20 0.38
ACHE P22303 1/20 0.38
MAPT P10636 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
HSD17B1 P14061 1/20 0.37
HSD17B2 P37059 1/20 0.37
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2856484 0.81 CSF1R (0.40) EGFRCSF1RTSHRCLK1CLK2
SCHEMBL795930 0.79 EGFR (0.46) EGFRCSF1RTSHRDYRK1AMEN1
SCHEMBL13338736 0.78 CSF1R (0.38) EGFRCSF1RTSHRACHEMAPT
SCHEMBL1697445 0.78 ACHE (0.55) EGFRCSF1RTSHRSMN1; SMN2ACHE
SCHEMBL13367477 0.74 KDM4C (0.46) EGFRCSF1RTSHRCLK1CLK2
SCHEMBL13367452 0.74 EGFR (0.40) EGFRSIGMAR1HTT
SCHEMBL2742923 0.72 ACHE (0.48) EGFRCSF1RTSHRSMN1; SMN2ACHE
SCHEMBL13367407 0.72 ACHE (0.55) EGFRCSF1RTSHRSMN1; SMN2ACHE
SCHEMBL13367476 0.71 KDM4C (0.44) EGFRCSF1RTSHRCLK1CLK2
SCHEMBL10042839 0.71 TSHR (0.46) EGFRCSF1RTSHRSMN1; SMN2ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100108997-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100108997-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same OR10J3, OCIAD1, OCIAD2 EGFR 1659/4885CSF1R 2428/4885TSHR 3278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.